Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV) platform to deliver its gene therapy, a distinct technology which Novartis hasn’t built up expertise in.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback